-
公开(公告)号：US12173070B2
公开(公告)日：2024-12-24
申请号：US17269784
申请日：2019-08-21
Applicant: ABL BIO INC.
Inventor： Eunyoung Park , Yangsoon Lee , Uijung Jung , YoungKwang Kim , Yeun Ju Kim , Youngdon Pak , Sang Hoon Lee , Weon-Kyoo You , Jaeho Jung , Lei Fang , Wenqing Jiang
Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.
-
公开(公告)号：US20240383983A1
公开(公告)日：2024-11-21
申请号：US18684660
申请日：2021-08-18
Applicant: ABL BIO, INC.
Inventor： Kyungjin PARK , Yangsoon LEE , Saeyi LIM , Kyeongsu PARK , Minkyu SEON , Wonjun SON , Hyejin CHUNG , Yeryoung YONG , Yong-Gyu SON , Yeunju KIM , Youngdon PAK
Abstract: The present disclosure provides an anti-B7-H4/anti-4-1BB bispecific antibody capable to effectively block the T-cell inhibitory effect of B7-H4 on the surface of tumor cells, and simultaneously activate 4-1BB on T-cells. The bispecific antibody may have high binding affinity to both of a B7-H4 protein (e.g., a human, monkey and mouse B7-H4 protein) and a 4-1BB protein (e.g., a human, monkey and mouse 4-1BB protein). The present disclosure also provides an anti-B7-H4 antibody specifically binds to B7-H4 protein.
-
公开(公告)号：US12122830B1
公开(公告)日：2024-10-22
申请号：US17057646
申请日：2019-05-23
Applicant: ABL Bio Inc.
Inventor： Yangsoon Lee , Juhee Kim , Kyungjin Park , Donghoon Yeom , Kyeongsu Park , Hyejin Chung , Yeunju Kim , Eunyoung Park , Ui-Jung Jung , Eunsil Sung , Jinhyung Ahn , Byungje Sung , Daehae Song , Youngdon Pak
IPC: C07K16/28 , A61K39/00 , A61P35/00 , G01N33/574
CPC classification number: C07K16/2803 , A61P35/00 , G01N33/57492 , A61K2039/505 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , G01N2333/705 , G01N2333/912
Abstract: The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.
-
公开(公告)号：US11891445B1
公开(公告)日：2024-02-06
申请号：US17057643
申请日：2019-05-24
Applicant: ABL Bio Inc.
Inventor： Kyeongsu Park , Yangsoon Lee , Hyejin Chung , Uijung Jung , Yong-Gyu Son , Sang-Jun Ha , Myeong Joon Kim , Eunyoung Park , Kyungjin Park , Eunsil Sung , Yeunju Kim , Jinhyung Ahn , Byungje Sung , Daehae Song , Youngdon Pak
IPC: C07K16/28 , G01N33/574 , A61P35/00 , A61K39/00
CPC classification number: C07K16/2827 , A61P35/00 , G01N33/57492 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2317/92 , G01N2333/70532
Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.
-
公开(公告)号：US20230405139A1
公开(公告)日：2023-12-21
申请号：US18209299
申请日：2023-06-13
Applicant: LegoChem Biosciences, Inc. , ABL Bio, Inc.
Inventor： Yun-Hee Park , Ho Young Song , Hyun Min Ryu , Sung Min Kim , Ju Yuel Baek , Ji Hye Oh , Nara Han , Hyoung Rae Kim , Kyung Eun Park , Hyeun Joung Lee , Ju Young Lee , Dae Hyuck Kang , Young-Jae Yang , Ji-na You , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Jinwon Jung , Juhee Kim , Bora Lee , Daehae Song , Byungje Sung , Donghoon Yeom , Jaehyun Eom , Youngeun Hong , Jinhyung Ahn , Yangsoon Lee , Kyungjin Park , Jiseon Yoo , Minji Park
CPC classification number: A61K47/6849 , A61P35/00 , A61K47/6803 , C07K16/2803
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
Patent Agency Ranking
公开(公告)号：US20230279085A1
公开(公告)日：2023-09-07
申请号：US16759937
申请日：2018-11-16
Applicant: ABL Bio Inc.
Inventor： Sang Hoon LEE , Weonkyoo YOU , Jinhyung AHN , Sungwon AN , Jinwon JUNG , Bora LEE , Dongin KIM , Byungje SUNG , Yonggyu SON , Yeunju KIM , Jaehyun EOM , Seawon AHN , Youngdon PAK , Donghoon YEOM , Daehae SONG
CPC classification number: C07K16/18 , G01N33/6896 , A61P25/28 , C07K2317/565 , C07K2317/567 , G01N2800/2821 , G01N2800/2835
Abstract: The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.
-
公开(公告)号：US20220056136A1
公开(公告)日：2022-02-24
申请号：US17298741
申请日：2019-02-15
Applicant: ABL BIO INC. , I-MAB BIOPHARMA CO., LTD
Inventor： Eunyoung PARK , Yangsoon LEE , Hyejin CHUNG , Eunsil SUNG , Jiseon YOO , Minji PARK , Yong-Gyu SON , Hyoju CHOI , Eunjung KIM , Jaeho JUNG , Weon-Kyoo YOU , Sang Hoon LEE , Lei FANG , Wenqing JIANG
Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.
-
公开(公告)号：US20210284749A1
公开(公告)日：2021-09-16
申请号：US17053256
申请日：2019-06-26
Applicant: ABL BIO INC.
Inventor： Kyungjin PARK , Hyejin CHUNG , Kyeongsu PARK , Yangsoon LEE , Mikyung CHANG , Jaehyoung JEON , Youngkwang KIM , Junhyun JEONG , Jiseon YOO , Yeunju KIM , Donghoon YEOM , Eunjung KIM , Bora LEE , Jinwon JUNG
Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.
-
9.发明授权公开(公告)号：US12071483B1
公开(公告)日：2024-08-27
申请号：US16770728
申请日：2018-12-14
Applicant: ABL Bio Inc.
Inventor： Jinhyung Ahn , Sungwon An , Dongin Kim , Eunsil Sung , Jaehyun Eom , Sang Hoon Lee , Weonkyoo You , Juhee Kim , Kyungjin Park , Hyejin Chung , Jinwon Jung , Bora Lee , Byungje Sung , Yeunju Kim , Yong-Gyu Son , Seawon Ahn , Daehae Song , Jiseon Yoo , Youngdon Pak , Donghoon Yeom , Yoseob Lee , Jaeho Jung
IPC: A61K39/395 , A61K47/68 , C07K16/18 , C07K16/28
CPC classification number: C07K16/2863 , A61K47/6845 , C07K16/18 , C07K2317/31 , C07K2317/565 , C07K2317/567
Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.
-
公开(公告)号：US11707533B2
公开(公告)日：2023-07-25
申请号：US16940326
申请日：2020-07-27
Applicant: LegoChem Biosciences, Inc. , ABL Bio, Inc.
Inventor： Yun-Hee Park , Ho Young Song , Hyun Min Ryu , Sung Min Kim , Ju Yuel Baek , Ji Hye Oh , Nara Han , Hyoung Rae Kim , Kyung Eun Park , Hyeun Joung Lee , Ju Young Lee , Dae Hyuck Kang , Young-Jae Yang , Ji-Na You , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Jinwon Jung , Juhee Kim , Bora Lee , Daehae Song , Byungje Sung , Donghoon Yeom , Jaehyun Eom , Youngeun Hong , Jinhyung Ahn , Yangsoon Lee , Kyungjin Park , Jiseon Yoo , Minji Park
CPC classification number: A61K47/6849 , A61K47/6803 , A61P35/00 , C07K16/2803
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.036 seconds)
